Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
11 supported by public sources, 0 supplied by the profile owner
Committee roles
2Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

J.D. who has served as General Counsel since July 2025. Previously served as General Counsel and Secretary at Rallybio Corporation and SpringWorks Therapeutics, and held senior legal positions at Alexion Pharmaceuticals.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies

Structured records are unavailable. This does not establish that no records exist.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Vistagen Therapeutics, Inc.

2021-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Vistagen Therapeutics, Inc.

Open Vistagen Therapeutics, Inc. profile →

Director at Vistagen Therapeutics, Inc.

2021-01-01 → End not stated

current · source reported

Observed: 2026-09-24

Vistagen Therapeut…Vistagen Therapeutics, Inc.Michael V. Greco, …

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingGPCR DEF 14A executive officersSupports Executive company, Executive title.Open sourceSource 2 · Sec FilingMANE 10-K executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open sourceSource 3 · Sec FilingKPTI 10-K executive officersSupports Executive company, Executive title.Open sourceSource 4 · Sec FilingVTGN DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Cybersecurity experience, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:mary-l-rotunno-j-d
Record version
public-0

Published evidence records

6 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. GPCR DEF 14A executive officers

    sec filing · Source published: Apr 23, 2026 · Retrieved: May 16, 2026

    Supports 2 claims
    • Executive company: Executive at Structure Therapeutics Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Chief Operating Officer and General Counsel · Claim reviewed: May 16, 2026

  2. MANE 10-K executive officers

    sec filing · Source published: Mar 30, 2026 · Retrieved: May 16, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Veradermics, Inc · Claim reviewed: May 16, 2026
    • Executive title: Executive title: General Counsel · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  3. KPTI 10-K executive officers

    sec filing · Source published: Feb 13, 2026 · Retrieved: May 16, 2026

    Supports 2 claims
    • Executive company: Executive at Karyopharm Therapeutics Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Executive Vice President, Chief Legal Officer and Secretary · Claim reviewed: May 16, 2026

  4. VTGN DEF 14A director slate

    sec filing · Source published: Jul 28, 2025 · Retrieved: May 16, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Audit, Corporate Governance and Nominating · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  5. Open source

    sec proxy · Source published: Jul 28, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at Vistagen Therapeutics, Inc. · Claim reviewed: May 16, 2026

  6. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Vistagen Therapeutics, Inc. · Claim reviewed: May 16, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board membership · Source reportedServes on the board of Vistagen Therapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedCommittee assignments: Audit, Corporate Governance and Nominating1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Karyopharm Therapeutics Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Structure Therapeutics Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Veradermics, Inc1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Chief Operating Officer and General Counsel1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Executive Vice President, Chief Legal Officer and Secretary1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: General Counsel1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources6 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  5. https://www.sec.gov/Archives/edgar/data/1411685/000141168525000052/vtgn-20250728.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at Vistagen Therapeutics, Inc. (NASDAQ: VTGN)

  6. https://www.sec.gov/Archives/edgar/data/1411685/000141168525000052/vtgn-20250728.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership